Why AbbVie Stock Slumped Today

AbbVie reported robust second-quarter results, surpassing analyst estimates with $15.4 billion in revenue and $2.97 adjusted EPS, driven by strong growth in Skyrizi and Rinvoq sales, and subsequently raised its 2025 earnings guidance. Despite these positive fundamentals, the stock's initial rally was negated by news of a White House directive from President Trump demanding drug price reductions from major pharmaceutical companies, including AbbVie, underscoring the significant regulatory risk facing the sector.

Analysis

AbbVie demonstrated strong operational performance in its second-quarter results, exceeding analyst consensus with revenue of $15.4 billion, a nearly 7% year-over-year increase, and an adjusted EPS of $2.97. The growth was primarily fueled by the successful commercial scaling of its key drugs Skyrizi and Rinvoq, which saw sales surge by 62% and 42% respectively, effectively offsetting the anticipated 58% revenue decline from Humira following its loss of exclusivity. Underscoring this fundamental strength, the company raised its full-year 2025 adjusted EPS guidance to a range of $11.88 to $12.08. However, this positive financial news was completely negated by a significant regulatory headwind. A directive from the White House demanding that AbbVie and other major pharmaceutical firms reduce prescription drug prices within 60 days erased the stock's initial post-earnings rally. This event highlights the substantial political and pricing risk that currently overshadows the company's robust fundamentals and positive operational outlook.

Key Decisions for Investors

• Investors should recognize the disconnect between AbbVie's strong fundamentals, evidenced by the earnings beat and raised guidance, and the stock's performance, which is being suppressed by significant regulatory headline risk.
• Monitor any developments related to the White House's demand for price reductions, as concrete policy actions could materially impact future revenue streams and profitability, overriding the positive trajectory of its growth products.
• For long-term investors, the price weakness resulting from political pressure could present a buying opportunity, provided they can tolerate the high degree of uncertainty associated with potential government-mandated price controls.